Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer

Inclusion Criteria: * Histologically confirmed non-squamous NSCLC, * Metastatic NSCLC of stage IV (according to American Joint Committee on Cancers) or recurrent NSCLC) * Patients without activating epidermal growth factor receptor (EGFR) mutation * Patients without anaplastic lymphoma kinase (ALK) rearrangement * Patients must have measurable lesion by RECIST 1.1 * Refractory disease defined by documented progression during the first-line chemotherapy based on a platinum doublet and third-generation drug (four or less cycles) according to RECIST V.1.1 * Age ≥18 years and \< 75 years * Performance status (PS) 0-1 * Life expectancy of more than 12 weeks. * No history of other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin. * Adequate organ function, evidenced by the following laboratory results within 3 weeks prior to randomization: Normal hepatic function: bilirubin \< 1.5 x N, ALT (alanine transaminase) and AST (aspartate aminotransferase ) \< 2.5 x N or \<5 x N in case of liver metastasis * Normal renal function (calculated creatinine clearance ≥ 45 mL/min). * Normal Calcemia * Normal haematological function (polynuclear neutrophils \> 1.5 G/l, platelets \> 100 G/l). * Anticoagulation with a vitamin K antagonist and low-molecular-weight heparin (LMWH) is authorized. * Antiplatelet treatment (aspirin authorized if \< 325 mg/d) * Treatment with dipyridamole, ticlopidine, clopidogrel is not authorized * Women of child bearing potential must use double effective contraception. * Men might be surgically sterile or accept to use an effective contraceptive procedure during and until 6 months after the treatment. * Written informed consent to participate in the study. Exclusion Criteria: * Known hypersensitivity to the trial drugs (nintedanib (vargatef®), docetaxel), peanut, soya, to their excipients * Controlled disease after first line treatment * Contra indication to the use of the backbone treatment * Patients who were withdrawn from first line treatment due to toxicity without documented disease progression or who received placebo (in the context of a clinical trial) as prior treatment are not eligible. * Previous treatment with docetaxel * Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer. * Previous therapy with vascular endothelial growth factor (VEGF) inhibitors except bevacizumab * Centrally located tumour with radiographic evidence of local invasion of local blood vessels * Radiographic evidence of cavitary or necrotic tumours at screening * Chemo-, hormone-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug. * Toxicity non resolute due to prior treatment \> grade I (except alopecia). * Radiotherapy (except extremities) within the past 3 months prior to baseline imaging * Persistence of clinically relevant therapy related toxicity from previous radiotherapy * Active brain metastases (e.g. stable for \<4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before inclusion). * Uncontrolled arterial hypertension. * Concurrent radiotherapy, except for palliative bone irradiation. * Other concurrent severe illnesses (congestive heart failure, unstable angina, significant arrhythmia or myocardial infarction less than 12 months before study entry). * Stroke less than 6 months before study entry. * Psychiatric or neurological disorders preventing the patient from understanding the nature of the trial * Grade \>=1 peripheral neuropathy * Uncontrolled infection. * Caval syndrome * Other organic disorders preventing inclusion in the trial * Malabsorption syndrome * Pregnancy and breast-feeding * Surgery less than two months before study entry. * Follow-up not feasible. * Incarcerated and institutionalized